Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth
— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb....
View HTML
Toggle Summary Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
- Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology - - Agreement provides Alexion with exclusive worldwide licenses as well as development and commercial rights for two...
View HTML
Toggle Summary Archemix and Dicerna to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics View HTML
Toggle Summary Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH) Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an...
View HTML
Toggle Summary Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) INGELHEIM, Germany & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Boehringer Ingelheim  and  Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA...
View HTML
Toggle Summary Dicerna Announces Addition to NASDAQ Biotechnology Index
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. ( NASDAQ : DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December...
View HTML
Toggle Summary Dicerna Announces Additional Patent Claims Allowed, Broadening Coverage of Extended Dicer Substrate Therapeutic Structures View HTML
Toggle Summary Dicerna Announces Allowance of Patent Claims Covering Extended Dicer Substrate Therapeutic Structures View HTML
Toggle Summary Dicerna Announces Appointment of Biotech Industry Leader Bruce Peacock to its Board of Directors and Audit Committee
WATERTOWN, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced today the appointment of Bruce Peacock to its board of directors and audit committee. Mr. Peacock currently serves as chief financial and business...
View HTML
Toggle Summary Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr....
View HTML